Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 40,000 shares at $43.53 ($1.7M) on 2023-08-16, disclosed to the SEC on 2023-08-17.
Scheduled sale ($1.7M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.77 | 10,000 | $438K | 25.1% |
| 2 | $43.77 | 10,000 | $438K | 25.1% |
| 3 | $43.53 | 10,000 | $435K | 25.0% |
| 4 | $43.18 | 10,000 | $432K | 24.8% |
| Total | $43.56 avg | 40,000 | $1.7M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |